Bolivia seeks to import COVID-19 vaccines from Biolyse, if Canada grants them a compulsory license

Today the government of Bolivia and Biolyse, a company based in Canada, signed an agreement to acquire COVID-19 vaccines manufactured by the company, if Canada grants them a compulsory license. Biolyse is a manufacturer of cancer drugs with the potential… Continue Reading

Luis Gil Abinader NIST comments on the definition of Subject Invention, 26 March 2021

PDF version here:LGA-NIST-Subject-Invention-definition-26March2021 More on the NIST proposed changes to the Bayh-Dole Regulations. https://www.keionline.org/35432 Comments of Luis Gil Abinader of Knowledge Ecology International on the redefinition of “Subject Invention” to Narrow the Inventions to Which Government Rights Attach (Modify 37… Continue Reading

Unredacted Pfizer contract with Dominican Republic, shows broad indemnity provisions for COVID-19 vaccine sales

On March 1, 2021, KEI obtained a copy of the binding term sheet between Pfizer/BioNTech and the Dominican Republic for the supply of their COVID-19 vaccine in the country. The document, requested via the freedom of information law in the… Continue Reading

Manufacturers of COVID-19 vaccines typically start delivering in under six months after tech transfer

Based on press releases and additional publicly-available information, KEI is building a dataset with a non-exhaustive list of deals that involve technology transfer and outsourcing of COVID-19 vaccines manufacturing. As of February 19, 2021, the dataset includes observations for over… Continue Reading

Foundational mRNA patents are subject to the Bayh-Dole Act provisions

Katalin Karikó and Drew Weissman are often described as the pioneers of the mRNA discoveries that underpin the first COVID-19 vaccines. In 2005 both scientists published a paper reporting that a slightly tweaked version of mRNA that can be administered… Continue Reading

U.S. Government funding of Lilly’s LY-CoV555 antibody against COVID-19

Lilly recently requested an emergency use authorization for LY-CoV555, an antibody treatment candidate against COVID-19. Like other COVID-19 candidates, the discovery of LY-CoV555 was heavily supported by the U.S. government. The government of Canada has also awarded millions to manufacture… Continue Reading

KEI panel on government funding of COVID drugs and vaccines at the Global Congress on Intellectual Property and the Public Interest

On October 5, 2020, KEI organized a panel about government funding of COVID-19 drugs and vaccines at the Global Congress on Intellectual Property and the Public Interest. Although the full Global Congress event was postponed to the year 2021, the… Continue Reading